New drug cocktail aims to outsmart Hard-to-Treat lymphoma
NCT ID NCT05507541
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of two drugs—TTI-622 and pembrolizumab (Keytruda)—in about 10 adults with diffuse large B-cell lymphoma that has come back or not responded to treatment. TTI-622 blocks a protein called CD47 that cancer cells use to hide from the immune system, while pembrolizumab helps immune cells attack the cancer. The study aims to find the safest dose and see if the combination can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TTI-622 (maplirpacept) and pembrolizumab (Keytruda)
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with hard-to-treat lymphoma that has returned or not responded to prior therapy.
- What could go wrong
- This is a very small early-phase trial (10 participants) focused on safety and dosing, so it is too soon to know if it will work. The combination may cause significant side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ALK POSITIVE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy combo shows promise for Tough-to-Treat blood cancers
- Engineered immune cells take on tough blood cancers in early trial
- New combo therapy aims to stop aggressive lymphoma relapse
- Brain training before CAR-T may protect memory, study hopes
- Triple-Target CAR T-Cells offer new hope for tough blood cancers
- New combo attack on lymphoma shows promise in early trial